tailieunhanh - Báo cáo y học: "Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: " Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference | Theoretical Biology and Medical Modelling BioMed Central Research Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women a different approach leads to new inference Babak Mohammadi Vahid Haghpanah Seyed Mohammad Tavangar and Bagher Larijani Open Access Address Endocrinology and Metabolism Research Center EMRC Tehran University of Medical Sciences Tehran Iran Email Babak Mohammadi - bbkmmd@ Vahid Haghpanah - vhaghpanah@ Seyed Mohammad Tavangar - emrc@ Bagher Larijani - emrc@ Corresponding author Published 9 June 2007 Received 27 April 2006 Theoretical Biology and Medical Modelling 2007 4 23 doi 1742-4682-4-23 Accepted 9 June 2007 This article is available from http content 4 1 23 2007 Mohammadi et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The diagnosis treatment and prevention of osteoporosis is a national health emergency. Osteoporosis quietly progresses without symptoms until late stage complications occur. Older patients are more commonly at risk of fractures due to osteoporosis. The fracture risk increases when suppressive doses of levothyroxine are administered especially in postmenopausal women. The question is When should bone mass density be tested in postmenopausal women after the initiation of suppressive levothyroxine therapy . Standard guidelines for the prevention of osteoporosis suggest that follow-up be done in 1 to 2 years. We were interested in predicting the level of bone mass density in postmenopausal women after the initiation of suppressive levothyroxine therapy with a novel .